ASTRAZENECA PLC (AZN)

ASTRAZENECA PLC (AZN)

Blog posts

Kentz, Victoria, AstraZeneca, and SSE

A number of companies on which ShareSoc has commented recently were in the news today (23/6/2014) or over the preceding weekend. Let's cover each in turn: Kentz Kentz received a cash offer for the company of 935p from SNC-Lavalin this morning. That's a premium of 33% to the recent share price. With such a premium and the stated support for the offer from the directors, it looks likely to succeed.  This will avoid the directors of Kentz having to deal with the ...

AstraZeneca and Pfizer merger definitely off

Pfizer have conceded defeat in their proposed offer for AstraZeneca (AZN). Ian Read, the Chief Executive of Pfizer, said it was a "missed opportunity" for both the UK and for AZN shareholders. He also said we could have had the worlds largest pharmaceutical company domiciled in the UK which would have been good for science and manufacturing in this country. He surely has a point there. In addition he complained about the Takeover Panel rules as contributing to thwarting the deal, but ...

Thoughts on AstraZeneca

Shareholders in AstraZeneca are no doubt pleasantly surprised by the uplift in the share price following the offers from Pfizer. The share price has doubled in the last year on improving prospects with an even sharper increase in the last few weeks as soon as a bid was rumoured. That puts the company on a historic p/e of about 20 at the time of writing. AstraZeneca has of course been a dog for some years with falling revenue and earnings, a poor ...

AGM Reports

Report on AstraZeneca (AZN) AGM 2014

Introduction As a shareholder I am pleased to observe that the company appears to have advanced considerably since the last AGM, in line with the strategy explained at the time by the then newly appointed CEO, Pascal Soriot (PS). The market perceived the company as having severe problems due to a “cliff” of patent expiries, impacting future revenues and profits. Astra’s pipeline of new products, to replace revenues & profits from products with expiring patents, was perceived as weak. As disclosed in the annual report and in the ...

Corporate Remuneration Reports

AstraZeneca Remuneration April Report 2016

Attached is the Manifest Report. Manifest Executive Remuneration Assessment grade 'D’ (on scale A =good to F=awful) Manifest has assessed the Company’s disclosures against the recommendations of the UK Corporate Governance Code, institutional investor guidelines and the disclosure requirements set out in both the Companies Acts and the UKLA Listing Rules. The following items have been identified which may be of interest to shareholders: Remuneration policy establishes a strong alignment between executive remuneration and Company strategy. Total remuneration awarded/received could be deemed ...

AstraZeneca Remuneration Report 2016

Attached is the Manifest Report. Manifest Executive Remuneration Assessment grade 'D’ (on scale A =good to F=awful). Manifest comment Shareholders may wish to note that this resolution previously recorded a high level of dissent with 39.31%. The targets used to determine the directors' annual bonus in respect of the year under review have not been fully disclosed. The level of the upper bonus cap for certain of the executive directors may be of concern. The aggregate of all long-term incentive awards made to Soriot represents ...